Neuropsychobiology
Biological Psychiatry. Main Editor: J. Mendlewicz (Brussels) / Original Paper
Association Study for a Functional Serotonin Transporter Gene Polymorphism and Late-Onset Alzheimer’s Disease for Chinese PatientsTsai S.-J.a,d · Hong C.-J.a,d · Liu T.-Y.c · Cheng C.-Y.a · Liu H.-C.b,eaDepartment of Psychiatry, bNeurological Institute, and cDepartment of Medical Research and Education, Veterans General Hospital-Taipei, Sections of dPsychiatry and eNeurology, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 14, 2001
Issue release date: June 2001
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1
ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)
For additional information: https://www.karger.com/NPS
Abstract
Two recent studies have demonstrated an association for a deletion/insertion polymorphism within the promoter region of the serotonin transporter gene (5-HTTLPR), and Alzheimer’s disease (AD). According to these studies, subjects with the short variant of the 5-HTTLPR gene are at increased risk for AD; however, this finding has not been confirmed by other workers. To evaluate the role of the 5-HTTLPR gene in susceptibility for AD, we conducted an association study for this polymorphism in a Chinese population. No significant differences were determined for genotype distribution or allele frequencies, comparing AD patients and normal controls. Even dividing the population into subgroups according to the presence of the APOE Ε4 allele, no differences for genotype or allele frequencies were determined, comparing patients and controls. These results suggest that it is unlikely that the 5-HTTLPR polymorphism plays a substantial role in conferring susceptibility to AD.
© 2001 S. Karger AG, Basel
Related Articles:
References
- Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N: Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet 1993;342:710–711.
- Hong CJ, Liu TY, Liu HC, Wang SJ, Fuh JL, Chi CW, Lee KY, Sim CB: Epsilon 4 allele of apolipoprotein E increases risk of Alzheimer’s disease in a Chinese population. Neurology 1996;46:1749–1751.
- Meneses A: 5-HT system and cognition. Neurosci Biobehav Rev 1999;23:1111–1125.
- Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF 3rd: Serotonin in aging, late-life depression, and Alzheimer’s disease: The emerging role of functional imaging. Neuropsychopharmacology 1998;18:407–430.
- Tejani-Butt SM, Yang J, Pawlyk AC: Altered serotonin transporter sites in Alzheimer’s disease raphe and hippocampus. Neuroreport 1995;6:1207–1210.
- Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621–2624.
- Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, Lesch KP, Powell J, Lovestone S, Collier D: Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer’s disease. Neuroreport 1997;8:683–686.
- Oliveira JR, Gallindo RM, Maia LG, Brito-Marques PR, Otto PA, Passos-Bueno MR, Morais MA Jr, Zatz M: The short variant of the polymorphism within the promoter region of the serotonin transporter gene is a risk factor for late onset Alzheimer’s disease. Mol Psychiatry 1998;3:438–441.
- Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S: Alzheimer’s disease and 5-HTTLPR polymorphism of the serotonin transporter gene: No evidence for an association. Am J Med Genet 2000;96:307–309.
- Zill P, Padberg F, de Jonge S, Hampel H, Burger K, Stubner S, Boetsch T, Jurgen Moller H, Ackenheil M, Bondy B: Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. Neurosci Lett 2000;284:113–115.
- Wang YC, Liu TY, Liu HC, Chi CW, Sim CB, Tsai SJ, Hong CJ: No association between 1-antichymotrypsin polymorphism and Alzheimer’s disease in Chinese. Neuropsychobiology 1999;40:67–70.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
- Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT: Presynaptic serotonergic markers in community-acquired cases of Alzheimer’s disease: Correlations with depression and neuroleptic medication. J Neurochem 1996;66:1592–1598.
- Du L, Faludi G, Palkovits M, Demeter E, Bakish D, Lapierre YD, Sotonyi P, Hrdina PD: Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry 1999;46:196–201.
- Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D: A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry 1998:3:328–332.
Article / Publication Details
Published online: June 14, 2001
Issue release date: June 2001
Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1
ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)
For additional information: https://www.karger.com/NPS
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
